XBRANE LEAD PRODUCT CANDIDATES

WORLD LEADING EXPERTISE IN DEVELOPING TRUE GENERICS FOR INJECTABLE CONTROLLED RELEASE DRUGS AND PROPRIETARY HIGH-YIELD PROTEIN EXPRESSION TECHNOLOGY.

Xbrane aims to pioneer the market of complex generics and enable global health equality by bringing affordable drugs to treat underserved people suffering from critical diseases. By combining proprietary technology and know how, Xbrane will develop affordable drugs for the global population. Here below you will find two of Xbrane’s lead candidates.

SPHEROTIDE

Introducing the world’s first generic to leading GnRH analogue.

Spherotide is a generic on the originator drug marketed under the trademarks Decapeptyl®/Trelstar®/Pamorelin® with controlled release of the active substance Triptorelin, a GnRH analogue used mainly in treatment of prostate cancer and endometriosis.

XLUCANE

Constantly outperforming industry standards by developing biosimilars with next generation technology.

Xlucane is a biosimilar on the originator drug sold under the trademark Lucentis® containing the protein ranibizumab as an active substance. Xlucane is used in the treatment of the wet form of age-related macular degeneration, an eye disease that leads to impaired vision and in worst cases even blindness.